May 07, 2026 —
REYON Pharmaceutical announced new 52-week clinical results for NG101, an investigational AAV-based gene therapy for wet age-related macular degeneration (wAMD) that it is co-developing with Elligene. The data were presented by Elligene at ARVO 2026 and focused on the low-dose cohort of an ongoing Phase 1/2a trial. According to the company, the presentation was selected as a “Hot Topic” by the ARVO program committee, reflecting its clinical and scientific relevance.
NG101 is designed to reduce the treatment burden for patients with wAMD, who often require repeated intravitreal anti-VEGF injections to maintain disease control. Public trial listings describe NG101 as an AAV gene therapy being evaluated by subretinal administration in patients with active wAMD, while earlier ARVO materials describe it as an AAV8 vector-based gene therapy encoding aflibercept.
In the reported low-dose cohort, patients had received an average of 9.8 anti-VEGF injections per year before trial enrollment. After NG101 administration, the average number of additional injections during the 52-week follow-up period decreased to 1.1. Among six participants, five maintained vision with no more than one additional injection, and three required no additional injections over the full year.
Key anatomical and functional measures, including best-corrected visual acuity (BCVA) and central subfield thickness (CST), were reported to remain stable. No serious adverse events or dose-limiting toxicities were observed in the low-dose cohort, supporting continued clinical development of the program.
REYON stated that NG101 has now completed dosing in 20 participants and that an interim report from the Phase 1/2a trial is expected in the third quarter of this year. The company plans to use the data to support discussions around technology out-licensing and future entry into a global Phase 2b trial. REYON also emphasized its role in global manufacturing and supply for NG101, supported by its GMP manufacturing capabilities and Chungju smart factory.
The results add to growing interest in ocular AAV gene therapy as a strategy to provide long-duration anti-VEGF expression and reduce the need for frequent injections in chronic retinal diseases. For wAMD, where treatment durability remains a major clinical and quality-of-life challenge, NG101’s early data suggest that AAV-mediated delivery could offer a potentially differentiated approach if safety, durability, and efficacy are confirmed in larger controlled studies.
